A5036086897- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Estrogen and related hormone effects
- Distributed and Parallel Computing Systems
- Gastric Cancer Management and Outcomes
- Educational Technology and Assessment
- Human Resource and Talent Management
- Competency Development and Evaluation
- Educational Robotics and Engineering
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Higher Education Learning Practices
- Medical Research and Treatments
- Cancer Diagnosis and Treatment
- Advanced Decision-Making Techniques
- Radiomics and Machine Learning in Medical Imaging
- Educational Reforms and Innovations
Chinese Academy of Medical Sciences & Peking Union Medical College
2025
Shanghai Medical College of Fudan University
2022-2024
Fudan University Shanghai Cancer Center
2022-2024
Changchun University
2007-2011
Harbin Engineering University
2004
Wuhan Engineering Science & Technology Institute
2004
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy optimal dosage trastuzumab deruxtecan (T-DXd) in managing human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. sought to assess cost-effectiveness T-DXd both United States (US) Chinese healthcare systems. Markov models were developed evaluate overall cost, incremental ratio (ICER), quality-adjusted life years (QALYs), (LYs)...
Background: The heterogeneity of estrogen receptor (ER) expression has long been a challenge for the diagnosis and treatment strategy metastatic breast cancer (MBC). A novel convenient method ER detection using 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) offers chance to screen analyze MBC patients with uncertainty. Methods: who received 18F-FES PET/CT were screened both FES positive (FES+) negative (FES-) lesions enrolled in this study....
Despite the promising efficacy of novel antibody-drug conjugate trastuzumab deruxtecan in treating Hormone Receptor (HoR)-positive/Human Epidermal Growth Factor 2 (HER2)-low metastatic breast cancer (MBC), its categorization as a distinct entity remains disputed, does divergence endocrine and chemotherapy outcomes. This study aimed to elucidate clinical characteristics, primary/metastatic lesion HER2 expression, treatment outcomes HoR-positive/HER2-low patients.We included...
With the approval of trastuzumab deruxtecan for treatment unresectable/metastatic HER2-low breast cancer, human epidermal growth factor receptor 2 (HER2)-low has emerged as a clinically actionable biomarker. There is an urgent need deeper understanding cancer patients. Therefore, this study was conducted to explore clinicopathological characteristics, evolution status, and its impact on prognosis hormone (HoR)-negative/HER2-low metastatic (MBC)
The 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) technique provides a convenient method to evaluate the overall estrogen receptor (ER) expression in metastatic breast cancer (MBC) patients. There are long debates on characteristics and treatment strategy of patients with positive primary ER lesions but negative disease. 18F-FES PET offers an opportunity answer this question.This study aimed characterize ER-positive advanced-stage FES negativity...
Objective Pyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy safety of pyrotinib plus trastuzumab (PyroH) (HP) in patients with HER2+ MBC. Methods We conducted a retrospective examination MBC who received PyroH chemotherapy or HP between 2017 2022 at five institutions China. primary endpoint progression-free survival (PFS). Results This involved 333 patients, among which 161 172 HP....
Vocational colleges actively respond to the national "The Belt and Road" strategy participate in practice of international cooperation running schools.However, main body vocational education is schools, which lacks effective participation enterprises, resulting unsatisfactory results.In order improve cooperation, this paper takes Chongqing Institute Engineering as an example, proposes a new mode called CEC for International education, makes detailed analysis mode.
1034 Background: The 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) technique provides a convenient method to evaluate the overall estrogen receptor (ER) expression in metastatic breast cancer (MBC) patients. There are long debates on characteristics and treatment strategy of patients with positive primary ER lesion but negative disease. 18F-FES PET offers an opportunity answer this question. Methods: This study enrolled MBC ER-positive tumor who...
e13058 Background: HER2-low positivity is more prevalent in breast cancers with positive hormone receptor (HR). Patients HR-positive and low HER2 expression may have different prognosis characteristics. Nevertheless, research focusing on HR-positive/HER2-low-positive cancer remains scarce. Methods: This study included 458 patients HR-positive/HER2-negative metastatic (HR+/HER2- MBC) who received first- or second-line endocrine therapy at the Fudan University Shanghai Cancer Center (FUSCC)...
Intra-tumoral heterogeneity of 18F-fluorodeoxyglucose (18F-FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value intra-tumoral metastatic Human epidermal growth factor receptor 2(HER2) positive breast cancer (MHBC) remains unknown. The aim this study was evaluate 18F-FDG predict dual target therapy with Trastuzumab and Pertuzumab(TP) MHBC. Thirty-two patients MHBC who underwent positron emission tomography/computed...
Trastuzumab, other innovative drugs became available, including lapatinib.Therefore, the Dushanbe City Counseling Center, together with Republican Cancer Institute and NGO Avesta, recruited humanitarian drug lapatinib to treat women metastatic cancer HER-positive status.A total of 56 advanced were selected.The primary diagnosis disseminated breast was in 19 (34%), relapse 37 women(66%).CNS metastases found 11 women, liver 26 women.Eleven (19%) received anthracycline therapy before...
Pyrotinib, an irreversible pan-human epidermal growth (HER) inhibitor, has proven its antitumor efficacy as a second-line treatment for HER2-positive metastatic breast cancer (HER2+ MBC) when combined with capecitabine. However, real-world data concerning the pyrotinib, trastuzumab, and chemotherapy (PyroHC) combination remains scarce.Our study is to report patterns, efficacy, safety of PyroHC in setting.This enrolled patients HER2+ MBC from five institutions China, treated between June 2017...